Biomea Fusion

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights. “Q2 2024 was another busy quarter for the company. The company’s top priority is working with FDA to resolve the clinical hold for BMF-219 in diabetes. We have made great progress with the second program, BMF-500 and our third program will be announced following the 60th European Association for the Study of Diabetes (EASD). Topline readout from the Phase 2b of COVALENT-111 with approximately 195 patients is on track for Q4 2024, and the topline readout from the Phase 2a of COVALENT-112 with approximately 20 patients is on track for Q4 2024,” stated Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board. #BiomeaFusion #DiabetesResearch #BMF219 #ClinicalTrials #HealthcareInnovation Visit us at biomeafusion.com and follow us on LinkedIn and Twitter for more updates! https://bit.ly/46wWML9

Happy #NationalAvocadoDay! Did you know that avocados can play a role in managing blood sugar levels? Their healthy fats and fiber make them a diabetes-friendly superfood! Today, we're celebrating the power of avocados and the strides we're making towards a diabetes-free future. Join us in honoring this nutritious fruit. Let's toast to good health and groundbreaking research! 🥑💚 #Biomeafusion #DiabetesResearch #HealthcareInnovation #Collaboration #FutureOfHealth

While Type 1 and Type 2 diabetes have distinct differences, both are chronic illnesses that can cause significant health problems and impact daily living. Our exciting research on the menin and beta cell interaction shows a promising approach to treating both Type 1 and Type 2 diabetes. To learn more about our exciting clinical research on diabetes, visit: https://lnkd.in/gci3AckU #Biomeafusion #DiabetesResearch #HealthcareInnovation #Collaboration #FutureOfHealth

Tired of generic Google answers to your questions on diabetes? We have answers on The Beaker, our own unique mix of information to help you understand the science behind what we do. 🧪 Ask us your questions at: https://lnkd.in/et-CiGuC #Biomeafusion #DiabetesResearch #HealthcareInnovation #Collaboration #FutureOfHealth

Attending the EASD 2024 Meeting in Madrid? If so, then please join us at the INNODIA "Shine a Light on T1D" Symposium on September 9, 2024 during the 2024 EASD Conference in Madrid, Spain! Dr Juan Pablo Frias, CMO and Head of Diabetes of Biomea Fusion will be just one of the many speakers who will provide information focused on therapies for type 1 diabetes. For attendees, this is a unique chance to learn about recent developments in the field and the therapies that are currently in development. Don’t miss this invaluable opportunity to engage with leading experts and contribute to the future of diabetes care. IMPORTANT: To attend the INNODIA "Shine a Light on T1D" Symposium, you must register by July 17, 2024. Register Here: https://bit.ly/3WnlcDo The Symposium is open to all, regardless of EASD Congress registration but you must be present to attend.

Congratulations, American Diabetes Association, 2024 Banting Medal Recipient Rory R. Holman. Emeritus Professor of Diabetic Medicine at the University of Oxford. Read his U.K. Prospective Diabetes Study 16 here: https://bit.ly/3L6ZvB4

Biomea Fusion had the pleasure of attending the American Diabetes Association's Women’s Interprofessional Networking Reception. This inspiring event brought together female clinicians, scientists, educators, and other health professionals involved in diabetes care and research. It served as a vital platform to amplify the voice and presence of women in the diabetes field, recognize their significant contributions, and facilitate networking among professionals with shared goals. The evening was filled with insightful presentations, meaningful discussions, and numerous opportunities for attendees to connect and share their insights. We left feeling motivated and empowered, and we're excited to support the ongoing efforts of women in the diabetes community. Thank you to everyone who made this event a success! #ADA2024 #WomenInDiabetes #Networking #Innovation

We're thrilled to kick off the first day of ADA2024 at booth #833 for Biomea Fusion! The energy is already buzzing, and we’re excited to engage with attendees about our latest innovations in diabetes research and treatment. A huge thank you to everyone planning to stop by today. If you haven’t had the chance yet, swing by booth #833 to learn more about how Biomea Fusion is shaping the future of diabetes care. See you soon! 👋 #ADA2024 #DiabetesResearch #Innovation

Learn about Biomea Fusion and how the protein menin is involved in diabetes and is a critical target in the development of new treatments. https://lnkd.in/gtg73Ani

What exactly is covalency? Check out our video to find out what a covalent molecule is and don't forget to explore our small covalent molecules hematological malignancies, solid tumors and hashtag #T2D at https://biomeafusion.com #ADA2024 #MeninProtein #BMEA #BiomeaFusion